---
title: "大和基于 2025 年全年收益，将辉瑞（PFE）的评级下调至中性"
description: "大和证券在辉瑞（PFE）发布 2025 年第四季度财报后，将其评级下调至中性。财报显示辉瑞的收入为 176 亿美元，每股收益为 0.66 美元，超出预期。然而，伯恩斯坦维持对辉瑞的市场表现评级，并将其目标价定为 30 美元，强调辉瑞是一只有前景的低成本股票"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275968662.md"
published_at: "2026-02-14T06:55:16.000Z"
---

# 大和基于 2025 年全年收益，将辉瑞（PFE）的评级下调至中性

> 大和证券在辉瑞（PFE）发布 2025 年第四季度财报后，将其评级下调至中性。财报显示辉瑞的收入为 176 亿美元，每股收益为 0.66 美元，超出预期。然而，伯恩斯坦维持对辉瑞的市场表现评级，并将其目标价定为 30 美元，强调辉瑞是一只有前景的低成本股票

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS \[…\]

### Related Stocks

- [IXJ.US - 标普全球医疗股指数 ETF - iShares](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [TBXU.US - Direxion Daily Biotech Top 5 Bull 2X ETF](https://longbridge.com/zh-CN/quote/TBXU.US.md)
- [XBI.US - 标普生物技术 ETF - SPDR](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [PBE.US - 动态生物技术与基因组 ETF - Invesco](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [FBT.US - 纽交所高增长板生物技术指数 ETF - First Trust](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [BIB.US - 2 倍做多纳斯达克生物技术 ETF - ProShares](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [XLV.US - 医疗业 ETF - SPDR](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [SBIO.US - 医药突破 ETF - ALPS](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [VHT.US - 医疗业 ETF - Vanguard](https://longbridge.com/zh-CN/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Basilea Pharmaceutica erhält Meilensteinzahlung für Cresemba-Verkäufe in Asien und China | Basilea Pharmaceutica AG announced a milestone payment of $5 million triggered by strong sales of its antifungal drug Cr | [Link](https://longbridge.com/zh-CN/news/275271671.md) |
| 07:59 ETPfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator | BaseLaunch has announced that Pfizer is the newest partner in its biotech venture incubator, increasing the total number | [Link](https://longbridge.com/zh-CN/news/275461886.md) |
| Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund | Pfizer has agreed to accept $29 million to settle a dispute with the SEC related to an insider trading case involving St | [Link](https://longbridge.com/zh-CN/news/275506783.md) |
| Basilea to Receive $5 Million Milestone Payment from Pfizer for Antifungal Drug | Basilea to Receive $5 Million Milestone Payment from Pfizer for Antifungal Drug | [Link](https://longbridge.com/zh-CN/news/275275339.md) |
| Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile | Valneva's IXCHIQ chikungunya vaccine faces new UK restrictions for individuals over 60 and those with specific health co | [Link](https://longbridge.com/zh-CN/news/275930832.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。